Mr Pinion has over 30 years of experience leading biologic, small molecule pharmaceutical, gene therapy and device operations across Asia, Europe and the Americas. He joined Ultragenyx in July 2015 and currently holds the role of EVP, Translational Sciences and Chief Quality Operations Officer. John is also an advisory board member for Celestial Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation novel and ground-breaking mRNA vaccines and therapeutics for the treatment and prevention of a variety of infectious diseases, rare diseases and cancers. John has previously held operational and senior leadership roles in Genentech (subsequently Roche post Genentech acquisition), as Senior Vice President and Global Head of Quality and Compliance for Pharma Technical Operations) and Baxter Internationals Renal, Bioscience, Parenterals and Device divisions. He is a Chair of the Risk Committee.
